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ABSTRACT
Introduction: Despite the availability of new
antibiotics such as daptomycin, methicillin-resistant
Staphylococcus aureus (MRSA) bacteraemia continues
to be associated with high clinical failure rates.
Combination therapy has been proposed as an
alternative to improve outcomes but there is a lack of
clinical studies. The study aims to demonstrate that
combination of daptomycin plus fosfomycin achieves
higher clinical success rates in the treatment of MRSA
bacteraemia than daptomycin alone.
Methods and analysis: A multicentre open-label,
randomised phase III study. Adult patients hospitalised
with MRSA bacteraemia will be randomly assigned
(1:1) to group 1: daptomycin 10 mg/kg/24 h
intravenous; or group 2: daptomycin 10 mg/kg/24 h
intravenous plus fosfomycin 2 gr/6 g intravenous. The
main outcome will be treatment response at week 6
after stopping therapy (test-of-cure (TOC) visit). This is
a composite variable with two values: Treatment
success: resolution of clinical signs and symptoms
(clinical success) and negative blood cultures
(microbiological success) at the TOC visit. Treatment
failure: if any of the following conditions apply: (1) lack
of clinical improvement at 72 h or more after starting
therapy; (2) persistent bacteraemia (positive blood
cultures on day 7); (3) therapy is discontinued early
due to adverse effects or for some other reason based
on clinical judgement; (4) relapse of MRSA
bacteraemia before the TOC visit; (5) death for any
reason before the TOC visit. Assuming a 60% cure rate
with daptomycin and a 20% difference in cure rates
between the two groups, 103 patients will be needed
for each group (α:0.05, ß: 0.2). Statistical analysis will
be based on intention to treat, as well as per protocol
and safety analysis.
Ethics and dissemination: The protocol was
approved by the Spanish Medicines and Healthcare
Products Regulatory Agency (AEMPS). The sponsor
commits itself to publishing the data in first quartile
peer-review journals within 12 months of the
completion of the study.
Trial registration number: NCT01898338.
INTRODUCTION
Methicillin-resistant Staphylococcus aureus (MRSA)
bacteraemia is of concern to healthcare
systems worldwide because of its high inci-
dence rates and poor outcomes. Mortality
rates range between 20% and 30%, which are
higher than those associated with methicillin-
susceptible Staphylococcus aureus (MSSA) bac-
teraemia.1 During the past decade, several
epidemiological changes have been observed
among patients with MRSA bacteraemia, such
as an upward trend in patient age, more
severe comorbidities, non-nosocomial health-
care acquisition and a non-intravascular
catheter source.2 These factors may be con-
tributing to the high-mortality rate. In add-
ition, one recent multicentre observational
study in 21 Spanish hospitals, which focused
on MRSA bacteraemia and included almost
600 episodes, found a mortality rate in excess
of 30%, regardless of the type of antibiotic
treatment administered.3
Vancomycin is still considered to be the
standard treatment for MRSA bacteraemia,
despite its association with poor patient out-
comes such as persistent bacteraemia, treat-
ment failure and nephrotoxicity.4 The higher
mortality rates associated with MRSA as com-
pared with MSSA bacteraemia have been
attributed to differences in host conditions,
microbial pathogenicity and especially to the
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inferior antistaphylococcal killing effect of glycopeptides
when compared with β-lactam antibiotics.5
The approval of daptomycin for treating MRSA bacter-
aemia and right-sided endocarditis has expanded the
therapeutic options for treating MRSA bacteraemia.
Daptomycin is a cyclic lipopeptide antibiotic with clinical
efﬁcacy at least as effective as that of vancomycin for
treating MRSA bacteraemia,6 and at the same time it
offers signiﬁcant advantages over the latter, such as a
more rapid bactericidal effect and less nephrotoxicity.4
Daptomycin exhibits concentration-dependent bacteri-
cidal killing activity and is generally safe and well toler-
ated at higher doses,7 although mortality rates,
particularly in patients with persistent or complicated
bacteraemia, have not declined signiﬁcantly.3 In one
multicentre randomised clinical trial that compared dap-
tomycin 6 mg/kg/d with vancomycin plus gentamicin
for the treatment of MRSA bacteraemia or right-sided
endocarditis, the success rate among patients treated
with daptomycin was 44%, compared to 32% in the
vancomycin–gentamicin group.8
There are increasingly favourable opinions concerning
the use of high-dose daptomycin, although no rando-
mised studies have been performed to support this
change. Based on expert opinion, current Infectious
Diseases Society of America (IDSA) clinical practice
guidelines recommend higher doses of daptomycin
(8–10 mg/kg/d) for the treatment of MRSA bacter-
aemia or infective endocarditis. The Spanish Society of
Infectious Diseases and Clinical Microbiology (SEIMC)
also recommends high-dose daptomycin (10 mg/kg/d)
for treating left-sided infective endocarditis.9 10 At
present, a daptomycin dosage of 8 mg/kg/day or more
is safe for patients with complicated MRSA infections.11
Failures of therapy with daptomycin due to persistent
or relapsing infection have been reported, especially in
complicated bacteraemia, and in some of these cases an
increase in daptomycin minimum inhibitory concentra-
tion (MIC) was also observed.6 Recent in vitro data
suggest that combination therapies might be an alterna-
tive to achieve better outcomes.12 13 Among them, dap-
tomycin in combination with rifampin or gentamicin
has not been associated with a better response in the
experimental model of endocarditis,14 15 while daptomy-
cin plus antistaphylococcal β-lactams, nafcillin or
cloxacillin was effective for treating patients with
refractory MRSA bacteraemia. The in vitro study showed
that β-lactams enhanced daptomycin bactericidal activity
by means of a reduction in membrane surface
charges.16
Fosfomycin is a phosphonic acid derivative that exhibits
bactericidal antimicrobial activity by binding to and subse-
quently inhibiting uridine diphosphate (UDP)-N-acetylglu-
cosamine enolpyruvyl transferase, an enzyme involved in
early-stage peptidoglycan synthesis. This unique mechan-
ism of action of fosfomycin makes cross-resistance to other
antibiotics highly unusual; furthermore, fosfomycin
retains activity against the majority of MRSA strains.17
However, it cannot be used alone because of the rapid
development of resistance.
There is limited experience of in vitro synergistic activ-
ity of fosfomycin in combination with β-lactams,
although it has been observed.18 In vitro and in vivo
synergy have also been observed between daptomycin
and fosfomycin in an MRSA experimental endocarditis
model,19 20 and the combination of daptomycin plus fos-
fomycin was at least as active as daptomycin plus cloxacil-
lin in the same MRSA experimental endocarditis
model.20 Indeed, some clinical cases of MRSA bacter-
aemia/endocarditis have been successfully treated with
the combination of daptomycin plus fosfomycin.19 21
In spite of these encouraging data, there is no con-
trolled clinical study comparing the efﬁcacy and safety
of daptomycin plus fosfomycin versus daptomycin alone.
Rationale
Despite the availability of new antibiotics such as dapto-
mycin, MRSA bacteraemia continues to be associated
with high clinical failure rates and poor outcomes.
Recent data suggest that combination therapies might
be an alternative to achieve better outcomes.12 13
Fosfomycin and daptomycin have recently been asso-
ciated with good clinical response.19 21 We hypothesize
that fosfomycin plus daptomycin will obtain higher clin-
ical response than a therapy with daptomycin alone.
Investigators chose daptomycin as a comparator instead
of vancomycin, which is still the standard therapy, because
in the last decades MRSA bacteraemia affects elderly
patients with more severe comorbidities2 who have higher
risk to renal impairment. In addition, vancomycin has
been associated with poorer outcomes in bacteraemia with
MRSA with elevated vancomycin MICs.22 23 MRSA strains
with vancomycin MIC ≥2 μg/mL have risen from 5.6% in
2004 to 11.1% in 2009, especially in some countries.24
Primary objective
To demonstrate that high-dose daptomycin combined
with fosfomycin achieves a better response than therapy
with high-dose daptomycin alone, measured in terms of
clinical success plus microbiological success (treatment
success) at week 6 after end of therapy (test-of-cure visit,
TOC).
Secondary objectives
Clinical secondary objectives
1. To compare the clinical success of daptomycin plus
fosfomycin versus daptomycin alone at end of therapy
(EOT).
2. To evaluate the safety of the daptomycin plus fosfomy-
cin combination compared with daptomycin alone.
3. To evaluate overall mortality between the two treat-
ment arms, daptomycin plus fosfomycin versus dapto-
mycin alone, at EOTand at week 6 after TOC.
Microbiological secondary objectives
1. To determine the frequency of persistent and relaps-
ing bacteraemia between the two treatment arms.
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2. To determine the emergence of daptomycin-resistant
strains during therapy in the two treatment arms.
3. To determine the emergence of fosfomycin-resistant
strains in the arm with fosfomycin treatment.
METHODS AND ANALYSIS
Study design
A multicentre, open-label, randomised, phase 3, inter-
ventional clinical trial stratiﬁed by centre with parallel
allocation (1:1). The trial has a superiority design.
Study population
Patients with complicated or uncomplicated MRSA bac-
teraemia hospitalised in participating hospitals.
Inclusion criteria
1. Patients must be ≥18 years old
2. Must have at least one blood culture positive for
MRSA in the 72 h up to randomisation
3. Written informed consent
4. Mandatory use of contraception methods for fertile
participants during the study period and for
6 months after stopping antibiotic therapy.
Exclusion criteria
1. Polymicrobial bacteraemia(more than one micro-
organism in blood cultures)
2. Participants with pneumonia
3. Severe clinical status with expected survival of less
than 24 h
4. Allergic to daptomycin or fosfomycin
5. A positive pregnancy test at the time of inclusion
6. Any clinical condition that requires additional anti-
biotic therapy with microbiological activity against
MRSA (speciﬁc forbidden antibiotics are named in
page 10, section: drugs accepted during the trial)
7. Patient is already included in another clinical trial
8. Severe liver disease (Child-Pugh score class C)
9. Prior history of eosinophilic pneumonia
Note: ≤72 h of active antibiotic therapy for MRSA
bacteraemia will not be considered a criterion for
exclusion
Setting
Patients will be recruited among different academic hos-
pitals of Spain located in Barcelona; Madrid; Seville;
Granada; Mallorca; Tarragona; Lleida; Barakaldo,
Valencia and Lugo.
List of study sites: Hospital Universitari de Bellvitge,
Hospitalet de Llobregat, Barcelona; Hospital Universitari
Clínic de Barcelona; Hospital Universitari Santa Creu i
Sant Pau, Barcelona; Hospital Universitari Vall d’Hebron,
Barcelona; Hospital Universitari Parc de Salut Mar,
Barcelona; Hospital Universitari Joan XXIII, Tarragona;
Hospital Universitari Arnau de Vilanova, Lleida; Hospital
Universitari Mutúa de Terrassa, Barcelona; Hospital de
Terrassa, Terrassa, Barcelona, Corporació Sanitaria Parc
Taulí, Sabadell, Barcelona; Hospital Universitario
Gregorio Marañón, Madrid, Hospital Universitario 12 de
Octubre, Madrid; Hospital Universitario Ramón y Cajal,
Madrid; Hospital Universitario Virgen Macarena, Sevilla;
Hospital Universitario Virgen de las Nieves, Granada;
Hospital Universitario de Cruces, Barakaldo; Hospital
Universitari i Politècnic la Fe, Valencia; Hospital
Universitari Son Espases, Mallorca; Hospital Universitario
Lucus Augusti, Lugo.
Recruitment of patients
Patients will be identiﬁed at each participating hospital
by checking daily for all blood cultures positive for
MRSA. Microbiologists will alert trial researchers to
assess for recruitment. Patients fulﬁlling all inclusion cri-
teria and none of the exclusion criteria will be assigned
in a randomised fashion to one of the treatment arms.
Randomisation and allocation concealment
A centralised electronic computer system will generate
random lists based on randomly permuted blocks.
Allocation sequences will be concealed by the system.
The programme will randomly assign participants on a
1:1 basis to two parallel groups in two treatment arms,
stratiﬁed by centre; 24 h web-based randomisation will
be provided.
Intervention
Patients will be randomly assigned to one of the follow-
ing arms:
1. Arm 1: Daptomycin 10 mg/kg intravenous, q/24 h
2. Arm 2: Daptomycin 10 mg/kg intravenous, q/24 h
plus fosfomycin 2 gr/6 h intravenous
Note: No more than 24 h must elapse between ran-
domisation and start of therapy.
Treatment of patients
Patients will receive the standard care of treatment for
MRSA bacteraemia from the attending physician and
study investigators will carry out extra scheduled visits.
Prescription of therapy
Daptomycin: 10 mg/kg, by intravenous infusion over a
period of 30 min, once a day. The recommended dosage
regimen for patients with creatinine clearance (CrCl)
<30 mL/min, including patients on haemodialysis or
continuous ambulatory peritoneal dialysis (CAPD), will
be 10 mg/kg once every 48 h.25
Note: Whenever possible on haemodialysis days, dap-
tomycin will be administered following completion of
haemodialysis.
Fosfomycin: 2 gr, by intravenous infusion over a period
of 2 h, every 6 h a day. If there is renal impairment, the
dose should remain constant (2 gr), with the interval
between administrations varying according to creatinine
clearance.26 (table 1).
Duration of therapy
Duration of therapy will be 10–14 days for uncompli-
cated bacteraemia and 28 days and up to 42 days for
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complicated bacteraemia. Cases of complicated bacter-
aemia considered by the PI to need 42-day therapy
should be discussed previously with the sponsor.
Drugs accepted during the trial
Concomitant use of any kind of drug is accepted during
the patient’s participation in the clinical trial, except for
antibiotics with activity against MRSA (rifampin, clindamy-
cin, trimethoprim-sulfamethoxazole, doxycycline, genta-
micin, linezolid, tigecycline and β-lactam antibiotics with
proven in vitro activity against MRSA in combination with
daptomycin as meropenem, piperacillin-tazobactam, clox-
acillin, ampicillin or cefepime).
In addition, temporary suspension of agents associated
with rhabdomyolysis, such as 3-hydroxy-3-methylglutaryl-
coenzyme A reductase inhibitors, should be considered
for patients receiving daptomycin.
Definitions
Complicated bacteraemia: will be deﬁned as patients
with MRSA in at least one blood culture with evidence
of spread of infection (metastatic infection), suspected
endocarditis, infection involving a foreign material that
cannot be removed in less than 4 days, or persistence of
a positive blood culture at 72–96 h from start of anti-
microbial therapy.
Uncomplicated bacteraemia: will be deﬁned as
patients with MRSA in at least one blood culture with
exclusion of endocarditis and no evidence of
haematogenous spread of infection at follow-up, plus
negative results for blood culture at 72–96 h from start
of antimicrobial therapy.
Participant timeline
All participants will be followed up by the study team for
6 weeks after stopping the study therapy. To assess
outcome, all patients will be visited on day 3, day 7 (only
if blood cultures at day 3 remain positive), weekly until
the EOT (EOT: at days 10–14, day 28 or day 42), then a
visit 6 weeks after stopping therapy (TOC). All data will
be recorded on electronic eCRF (see ﬁgure 1; online
supplementary appendix 1 shows the clinical trial
assessment).
OUTCOMES
Primary end point
Treatment response at the TOC visit. This is a composite vari-
able with two values.
Treatment success will be deﬁned as the resolution of
all clinical signs and symptoms (clinical success) plus
negative blood culture (microbiological success) at the
TOC visit.
Treatment failure will be deﬁned as any of the follow-
ing situations: (1) lack of clinical improvement at 72 h
or more after the start of therapy; (2) persistent bacter-
aemia (positive blood culture on day 7 after the start of
therapy); (3) premature discontinuation of therapy due
to adverse effects or for any other reason based on clin-
ical judgement; (4) relapsing MRSA bacteraemia before
the TOC visit; (e) death for any reason before the TOC
visit.
Secondary end point
▸ Treatment success at EOT visit (clinical success +
microbiological success)
▸ Mortality at EOT and the TOC visit
▸ Severe adverse effects
Figure 1 Participant timeline.
Table 1 Prescription of therapy
Creatinine clearance Doses
40–20 mL/min 2 g every 12 h
20–10 mL/min 2 g every 24 h
≤10 mL/min 2 g every 48 h
Dialysis 2 gr following haemodialysis session
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▸ Persistent MRSA bacteraemia
▸ Recurrence of MRSA bacteraemia (positive blood
culture when previous ones were negative)
▸ Emergence of daptomycin resistance
▸ Emergence of fosfomycin resistance
▸ Days until negative results of blood culture
▸ Days to death
▸ Days to treatment failure
Note: Eucast Clinical break points have been consid-
ered to deﬁne daptomycin and fosfomycin susceptibility
that were above 1 and 32 mg/L, respectively.
Criteria for withdrawing a patient from the study
Patients must be withdrawn from the study in any of the
following situations:
▸ The criteria for clinical failure are fulﬁlled at 72 h
after start of therapy (worsening of sepsis signs or
symptoms).
▸ The criteria for treatment failure are fulﬁlled (posi-
tive MRSA blood culture on day 7 after start of
therapy).
▸ The patient asks to be withdrawn from the study (at any
time during the patient’s participation in the study).
▸ A new clinical condition makes it necessary to add a
new antimicrobial (different from those used in the
study) with activity against MRSA.
▸ The principal investigator (PI) considers that there
has been a serious protocol violation.
▸ The following occur during therapy: CPK values are
>5, the upper limit of normal (ULN) plus muscle
symptoms (cramps, muscle pain, weakness); signs or
symptoms of peripheral neuropathy or suspicion of
eosinophilic pneumonia.
▸ Any adverse event for which the clinicians consider
that it is necessary to withdraw antibiotic therapy.
▸ Lost to follow-up.
▸ Pregnancy during the study.
Note: The following will not be considered a cause for
withdrawal: any surgical intervention, such as debridement
of an abscess, device removal and prosthesis valve replace-
ment during therapy, since these are considered part of
the standard care for complicated MRSA bacteraemia.
Managing withdrawals
When a patient has been withdrawn from the study, the
investigator will record the reason/s for withdrawal on
the clinical chart and the eCRF. If possible, all early with-
drawal patients will be assessed up to the EOT visit. If
the reason for withdrawal was a serious adverse event,
the patient must be followed until the resolution or sta-
bilisation of the event.
Note: Patients who withdraw early will not be replaced.
STATISTICAL ANALYSIS PLAN
Sample size and power calculations
We have assumed a 60% treatment success rate in the
daptomycin group (based on success rates at the end of
therapy shown in Fowler’s clinical trial). Accepting an α
risk of 0.05 and a β risk of 0.2 in a two-sided test, 103
patients per group would be necessary to ﬁnd a statistic-
ally signiﬁcant difference of 20% between treatment
groups. A dropout rate of 20% has been anticipated.
Type of analysis
To assess differences between study groups in baseline vari-
ables and other efﬁcacy end points, two independent
sample procedures will be employed. Continuous variables
will be compared using parametric t tests or non-
parametric Mann-Whitney U tests, depending on whether
the distribution can be assumed to be normal (after per-
forming tests for normality). Categorical data will be com-
pared by the χ2 or Fisher’s exact tests, as appropriate.
Survival curves will be compared by means of the log-rank
test. Logistic or Cox regression models will be used to
explore associations between different efﬁcacy end points,
interventions and relevant baseline conditions, using two-
sided tests and a 5% signiﬁcance level.
A logistic regression model will be used to assess the
effect of important prognostic factors on response to
treatment. Covariates at a 0.10 level of signiﬁcance in the
univariate analysis will be included in the multivariate
analysis. In addition, each component of the composite
end point treatment response will be analysed separately.
Efﬁcacy analyses will be performed for the intention-
to-treat (ITT) population. Given that patients will be hospi-
talised during antibiotic treatment and close follow-up is
expected, this population will consist of all randomised par-
ticipants. To account for dropouts between end-of-therapy
and TOC visits, we will explore the various dropout pat-
terns and their impact on response. Appropriate multiple
imputation procedures will be employed to account for
missing data for treatment response. When analysing sur-
vival analysis end points (time to death, time to negative
blood culture, time to treatment failure), relevant patients
will be censored at the time of withdrawal. Safety analyses
will be performed on all randomised patients.
MONITORING
Monitoring plans
The data monitoring board will ensure the correct pro-
gress of the research and the efﬁcacy of the data towards
achieving the goals of the study
A safety monitoring committee with independent investi-
gators will review safety data and provide advice about the
continuation, modiﬁcation and/or termination of the
study.
ADVERSE EVENTS REPORTING AND QUANTIFICATION
Definitions
Adverse event: any injury related to medical management
(including all aspects of care) that occurs during the
patient’s participation in the clinical trial will be consid-
ered an adverse event. An adverse event may be related
to the study medication or be non-related.
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Adverse drug event: any medication-related adverse
event occurring during the patient’s participation in the
clinical trial will be considered an adverse drug event.
Adverse drug reaction: any ‘adverse drug event’ that occurs
when the medication is used as directed and in the usual
dosage will be considered an adverse drug reaction.
Serious adverse event or reaction will be deﬁned as an
event or reaction that:
▸ Results in death
▸ Is life-threatening
▸ Causes persistent or signiﬁcant disability
▸ Causes a congenital anomaly/birth defect
▸ Requires in-patient hospitalisation or prolongation of
existing hospitalisation (not related to basal diseases)
Grading of adverse event or reaction: will be performed in
accordance with the Division of Microbiology and
Infection Diseases (DMID) adult toxicity table, May 2001.
Adverse drug event of particular interest for the study
▸ Diarrhoea: A stool test for detecting Clostridium
difﬁcile-associated diarrhoea should be considered if the
patient develops diarrhoea during the study. The occur-
rence of this adverse event will not lead to discontinu-
ation of the drug, unless the PI considers it necessary.
▸ Elevated creatine phosphokinase (CPK): CPK levels >5
times the upper limit of normal (ULN)+symptoms
(cramps, muscle pain, weakness) should lead to dis-
continuation of study medication and early patient
withdrawal. For asymptomatic patients, a CPK >10
times the upper limit of normal (ULN) will be
required for drug discontinuation. These adverse
events should be notiﬁed to the sponsor.
Reporting
Any adverse event and its relationship to the study drug
occurring during the patient’s participation in the clin-
ical trial should be recorded by the PI on the clinical
chart at every scheduled visit.
On the electronic eCRF, there should only be recorded:
serious adverse drug events; adverse events of any grade
related to the study medication, in the opinion of the PI;
adverse events of any grade leading to modiﬁcation of
study drug dosage, its interruption/early discontinuation.
All serious adverse events should be notiﬁed to the
sponsor within 24–48 h of the investigator becoming
aware of the event.
ETHICAL ISSUES
The trial will be conducted according to the principles of
the Declaration of Helsinki (2008) and current Spanish
legislation (Real decreto 223/2004). The principal investi-
gator or collaborator at each site will obtain written
informed consent from all patients, or their legal represen-
tatives (LRs) if they lack capacity, before enrolment.
Patients (or their LRs) are free to withdraw from the trial at
any time and this will be explicitly stated on the patient’s
information sheets (see online supplementary appendix 2).
The data collected for the study will be identiﬁed by a
code and only the study doctor and collaborators will be
able to link those data with patients and their clinical
history. Consequently, the patient’s identity will not be
revealed to any other person, except in cases of medical
emergency or if required to do so by law.
Access to patient information will be restricted to the
study doctor and collaborators, the health authorities
(Spanish Medicines and Healthcare Products Regulatory
Agency (AEMPS)), the Clinical Research Ethics
Committee, and personnel authorised by the sponsor
when they need to check the data and procedures used in
the study, but always maintaining the conﬁdentiality of the
said information in accordance with current legislation.
The trial protocol received research ethics committee
approval in July 2013. Amendment was approved in June
2014 (V.4. 30th April 2014).
The informed consent form and information sheet
received research ethics committee approval in July 2013
and AEMPS approval in September 2013.
Indemnities
In accordance with Spanish legislation governing clinical
trials (RD 223/2004), this study has liability insurance
covering possible damages to patients during their par-
ticipation in the study, Zurich Insurance PLC, Spanish
branch, policy number 70383054.
Publication plans
The sponsor commits itself to publishing the data within
12 months of the completion of the study. Results will be
analysed and reported in accordance with CONSORT
guidelines.
Protocol amendments
For communicating important protocol modiﬁcations, we
will ﬁrst notify the Clinical Research Ethics Committee and
Spanish Medicines and Healthcare Products Regulatory
Agency (AEMPS) in accordance with Spanish legislation.
After their approval, all the Ethics Committee members
and investigators of the participating sites will be informed.
DISCUSSION
Currently, there is a need to improve cure rates of
patients with MRSA bacteraemia. Some in vitro studies
showed a synergistic activity of fosfomycin in combin-
ation with β-lactams.18 In addition, some patients with
MRSA bacteraemia have recently been successfully
treated with the combination of daptomycin and fosfo-
mycin.19–21
We designed this open-label randomised study to dem-
onstrate the hypothesis that fosfomycin (2 gr every 6 h
a day) in combination with daptomycin (10 mg/kg once
a day) will be better therapy for treating patients with
MRSA bacteraemia than therapy with daptomycin alone.
Therefore, the study design includes patients with
uncomplicated and complicated MRSA bacteraemia,
and the main end point includes clinical success plus
microbiological success at week 6 after EOT (TOC visit)
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Expected impact: this trial will help provide a response
to the priority clinical question of whether treatment
with daptomycin plus fosfomycin reduces mortality rates
and also improves clinical outcomes associated with
MRSA bacteraemia.
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Xercavins, Susana Redondo. Hospital de Terrassa: Josefa Perez, Manuela
Gonzalez. Corporació Sanitaria Parc Taulí, Sabadell: Dionisia Fontanals, Miquel
Cruel. Hospital Universitario Gregorio Marañón, Madrid: Emilia Cercenado,
Ana Mur. Hospital Universitario 12 de Octubre, Madrid: Tiago Sequeira,
Fernando Chaves; Vicente Gallego. Hospital Universitario Ramón y Cajal,
Madrid: Elena Loza, Cristina Pueyo, María Muñoz. Hospital Universitario
Virgen Macarena, Sevilla: Isabel Morales, Marina de Cueto, Jose Manuel
Carretero. Hospital Universitario Virgen de las Nieves, Granada: M Perez, Inma
Zafra. Hospital Universitario de Cruces, Barakaldo: Mercedes Sota, Alazne
Bustinza. Hospital Universitari i Politècnic la Fe, Valencia: Eva Gonzalez, Jose
Luis López, Maria Tordera, Hospital Universitario Son Espases, Mallorca:
Antoni Campins, Enrique Ruiz de Gopegui, Antonio Palomero. Hospital
Universitario Lucus Augusti, Lugo: Juan Corredoira, Fernando Garcia, Araceli
Iglesias. Note: Administrative information sheet and microbiological
procedures are included in online supplementary appendix 3 and appendix 4.
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